title: Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment.
abstract: BACKGROUND
  Serum albumin level is correlated with outcome in various clinical situations. Albumin has multiple physiologic properties that could be beneficial in brain injury. The Lund therapy for elevated intracranial pressure uses albumin as part of its protocol and demonstrates favorable outcome. We sought to find out if albumin is associated with outcome after traumatic brain injury to justify conducting a randomized trial.
  
  
  METHODS
  A retrospective study of traumatic brain injury patients was conducted. Characteristics known to influence outcome were included in a multiple logistic regression model to analyze predictors of poor outcome at 6 months.
  
  
  RESULTS
  Data were available for 138 patients. The majority of patients (65%) had a severe injury (Glasgow Coma Scale score <9). Seventy percent of patients had a favorable outcome. Albumin levels decrease considerably from normal values in the first few days after injury irrespective of outcome. Albumin remained <25 g/L for a longer period of time in patient with an unfavorable outcome (6 days vs. 3 days, p = 0.012). Multiple logistic regression analysis identified albumin levels, age, Glasgow Coma Scale score at admission, and Injury Severity Score as predictors of poor outcome.
  
  
  CONCLUSIONS
  Serum albumin level seems to be an independent predictor of poor outcome. The model also identified classic predictors of poor outcome that tends to strengthen its adequacy. Because albumin level is the only modifiable factor influencing outcome, it seems justified to carry out a randomized trial of the use of albumin in the treatment of brain injury.
authors.affiliation: University Department of Critical Care Medicine, Hôpital du Sacré-Coeur, Montréal, Québec, Canada. bernard.francis@gmail.com
authors.forename: Francis
authors.initials: F
authors.lastname: Bernard
authors.forename: Yahia Z
authors.initials: YZ
authors.lastname: Al-Tamimi
authors.forename: Doris
authors.initials: D
authors.lastname: Chatfield
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Lynch
authors.forename: Basil F
authors.initials: BF
authors.lastname: Matta
authors.forename: David K
authors.initials: DK
authors.lastname: Menon
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001930:Brain Injuries / Q000097:blood* / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy; D002423:Cause of Death; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D015600:Glasgow Coma Scale; D006801:Humans; D015601:Injury Severity Score; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis*; D016019:Survival Analysis
chemical_list: D015415:Biomarkers; D012709:Serum Albumin